NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced today that it will participate in the Planet MicroCap Las Vegas 2026 Conference, scheduled for June 17-18, 2026. President and CEO Dave Rosa will attend the conference in Las Vegas, Nevada, where he is set to host one-on-one meetings with institutional investors and deliver a company presentation on Wednesday, June 17, 2026, at 12:00 p.m. Pacific Time in TRACK 6 - Raphael 3. The presentation will focus on commercialization updates and anticipated milestones for the OneRF platform, which is used for treating brain disorders, pain, and advanced drug delivery.
This announcement is significant for NeuroOne as it provides a platform to communicate directly with potential investors and the broader financial community. The conference is a key event for micro-cap companies seeking visibility and capital. Mr. Rosa's participation, including a pre-recorded CEO interview with Planet MicroCap host Robert Kraft, underscores the company's efforts to increase awareness of its technology and growth prospects. The interview can be viewed here.
NeuroOne's technology portfolio includes four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for the brain, and OneRF Trigeminal Nerve Ablation System. These products aim to reduce hospitalizations and surgical procedures while improving patient outcomes. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
The Planet MicroCap Las Vegas 2026 Conference will take place at the Tropicana Las Vegas. More information about the conference and the company's presentation can be found on the conference website here. Investors interested in scheduling a meeting with management can contact their conference representative or email NMTC@mzgroup.us.
NeuroOne's participation in this conference is crucial for its growth strategy, as it allows the company to showcase its innovative solutions and progress to a targeted audience of investors. The OneRF platform, in particular, represents a significant advancement in the treatment of neurological disorders, and the company's updates could influence investor sentiment and the stock's performance. As NeuroOne continues to commercialize its products and expand its pipeline, events like the Planet MicroCap Conference serve as vital opportunities to communicate its value proposition and milestones.
